Amarin Corporation PLC logo

Amarin Corporation PLC(AMRN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$11.38
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AMRN

11/13/2026: AMRN (1-star) is currently NOT-A-BUY. Pass it for now.

Amarin Corporation PLC is a specialized biopharmaceutical company focused on commercializing cardiovascular therapies, anchored by its clinically validated flagship product Vascepa. The company's main business strengths include established brand credibility from the REDUCE-IT trial, a debt-free balance sheet with over $323 million in cash, and a successful restructuring that restored quarterly profitability. Its primary growth story centers on expanding international market adoption through key partnerships in Europe and Asia. However, the company faces substantial risks from aggressive generic competition and declining US revenue pricing pressures. Amarin suits risk-tolerant investors looking for a leaner turnaround play with strong cash reserves, requiring close monitoring of international partner sales growth and ongoing cost discipline.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitTop-line revenue is contracting due to generic erosion, limiting near-term organic growth potential.
Momentum investorStrong fit while signal remains positiveMomentum appeal remains conditional on positive breakout signals or earnings surprises following recent quarterly profitability.
Value investorMixed fitThe company trades at a reasonable discount backed by substantial net cash, though declining revenues add structural uncertainty.
Dividend investorWeak fitAmarin does not pay dividends, rendering it unsuitable for income-focused investors.
Low-risk investorWeak fitHigh equity price volatility and single-product concentration create considerable risk profile exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings driven by shifting quarterly revenue and generic litigation updates.
Valuation riskMediumValuation is cushioned by substantial cash reserves, but compressed earnings multiples reflect top-line uncertainty.
Competition risk (generic drug and branded cardiovascular competition)HighGeneric icosapent ethyl entrants continue to capture volume and compress net selling prices in the US market.
Business qualityMediumWhile Vascepa is clinically validated, heavy reliance on a single product exposes the franchise to structural vulnerability.
Dividend incomeLow / noneAmarin offers zero dividend yield as all cash is prioritized for operational stability.
Execution riskMedium / highSuccess relies heavily on executing international partnerships and managing cost controls effectively.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 478.44M USD
Price to earnings Ratio -
1Y Target Price 13
Price to earnings Ratio -
1Y Target Price 13
Volume (30-day avg) 76.7K shares
Beta 0.79
52 Weeks Range 11.25 - 17.31
Updated Date 11/15/2026
52 Weeks Range 11.25 - 17.31
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.8

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 37.06%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AMRN receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
AMRN has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+52.8%) is partially offset by soft cash generation (FCF margin 3.2%), negative revenue growth (-6.5%), weak profitability (net margin -18.2%).

Financial Health Rating

★★★★★
AMRN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 67.9%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is AMRN's strongest growth driver at +121.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+52.8%, strong) is also strong, while revenue growth (-6.5%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.8% and approximately 46.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 37.19% supports management-shareholder alignment.

Top 5 Institutional Investors

Sarissa Capital Management LP 3.98%
Acadian Asset Management LLC 1.74%
Kynam Capital Management, LP 1.27%
Morgan Stanley - Brokerage Accounts 0.53%
Waterfront Wealth Inc. 0.51%

Unit Economics (Per $1K Revenue)

★★★★★
AMRN generates approximately $566 of gross profit, $-65 of operating income, and $32 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -7.63% (Tax Credit)

Quantitative Style Profile

★★★★★
AMRN has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
United States Product RevenueDirect sales of Vascepa prescription capsules to wholesalers, distributors, and pharmacy providers in the US market.This is the primary revenue stream, though it faces ongoing pricing pressures from generic competitors.
International Licensing and RoyaltiesCommercialization fees, product supply sales, and milestone royalties from overseas partners like Recordati and Mochida.International expansion through trusted partners acts as an increasingly important driver of global volume growth.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-28
When Before Market
Estimate -0.28
Actual 0.01

Profitability

Profit Margin -10.87%
Operating Margin (TTM) -13.97%

Management Effectiveness

Return on Assets (TTM) -2.38%
Return on Equity (TTM) -4.24%

Valuation

Trailing PE -
Forward PE 500
Enterprise Value -78.35M
Price to Sales(TTM) 2.72
Enterprise Value -78.35M
Price to Sales(TTM) 2.72
Enterprise Value to Revenue -
Enterprise Value to EBITDA -5.8
Shares Outstanding 42.04M
Shares Floating 19.36M
Shares Outstanding 42.04M
Shares Floating 19.36M
Percent Insiders 37.19
Percent Institutions 20.84

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.